Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise ...
With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...
They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...
The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
Southwest District Health ended its COVID-19 vaccination program. Others in Texas, Florida and Michigan also pushed back against the vaccine.
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
6d
Like humans and other complex multicellular organisms, single-celled bacteria can fall ill and fight off viral infections. A ...
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback